Study to Assess the Efficacy and Safety of Sitagliptin in Recently Diagnosed, Naive Type 2 Diabetics With Inadequate Glycemic Control on Diet and Exercise (0431-158)

Merck Sharp & Dohme (MSD)

Status and phase: Completed; Phase 4

Conditions: Diabetes Mellitus

Treatments: Drug: sitagliptin phosphate

Study type: Interventional

Funder types: Industry

Identifiers

NCT00832390

0431-158

2009_525

Details and patient eligibility

About

After 24 weeks of treatment evaluate the efficacy and security.

Enrollment: 29 patients

Sex: All

Ages: 30 to 78 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Patients Being Treated With Metformin
• Patients With Hba1c Between 6.5 % And 12.0%.
• Type 2 DM

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

29 participants in 1 patient group

1

Experimental group

Description:

sitagliptin

Treatment:

Drug: sitagliptin phosphate